Brendel Financial Advisors’s Biogen BIIB Stock Holding History

Brendel Financial Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-48	Closed	-$17K	–	89
2021 Q2	$17K	Buy	+48	New	+$14.5K	0.01%	196

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Brendel Financial Advisors's BIIB Position: Q3 2021 in Review

Brendel Financial Advisors sold out of Biogen (BIIB) in Q3 2021, closing a stake of 48 shares — an estimated $17K sold.

Brendel Financial Advisors first reported a position in BIIB in Q2 2021 and held it in 1 quarter. The position peaked at $17K in Q2 2021. 1,039 funds tracked by Wall St. Rank hold BIIB as of Q3 2021.

Brendel Financial Advisors reported no remaining Biogen position as of Q3 2021 after selling out during the quarter.
Brendel Financial Advisors sold 48 Biogen shares in Q3 2021, an estimated $17K.
Brendel Financial Advisors first reported a position in Biogen in Q2 2021 and held it in 1 quarter.
Brendel Financial Advisors's Biogen position peaked at $17K in Q2 2021.
1,039 funds tracked by Wall St. Rank held Biogen as of Q3 2021.

Based on Brendel Financial Advisors's 13F filing for Q3 2021, filed 26 Oct 2021.